Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review

Lao, Juan; Madani, Julia; Puértolas, Teresa; Álvarez, Manuel; Hernández, Ana Jesús; Pazo-Cid, Roberto; Artal, Ángel; Torres, A. Antón

doi:10.1155/2013/456409

Cited by 137 publications

(94 citation statements)

References 61 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hydrophilic and hydrophobic bilayer cores entrap hydrophilic and lipophilic drugs, respectively. Liposomes have been demonstrated to prolong the blood-circulation time of drugs, to alter the pharmacokinetics and distribution of P-gp inhibitors in vivo, and to increase the drug concentration in the tumor cells, while reducing the impact on normal tissues, thus exerting toxicity to enhance the effects of chemotherapy (15)(16)(17)(18)(19)(20)(21). A study by Zhou et al (22), which investigated MDR reversal using doxorubicin (DOX) liposomes in vitro, demonstrated that DOX liposomes were mainly detected in the nucleus of human breast cancer P-gp overexpression cells (MCF-7/Adr) with an increased toxicity, and exhibited a stronger cellular retention capacity in human carcinoma KBv200 cells.…”

Section: Liposomesmentioning

confidence: 99%

Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer

et al. 2016

View full text Add to dashboard Cite

Abstract. Multidrug resistance (MDR) to chemotherapy presents a major obstacle in the treatment of cancer patients, which directly affects the clinical success rate of cancer therapy. Current research aims to improve the efficiency of chemotherapy, whilst reducing toxicity to prolong the lives of cancer patients. As with good biocompatibility, high stability and drug release targeting properties, nanodrug delivery systems alter the mechanism by which drugs function to reverse MDR, via passive or active targeting, increasing drug accumulation in the tumor tissue or reducing drug elimination. Given the potential role of nanodrug delivery systems used in multidrug resistance, the present study summarizes the current knowledge on the properties of liposomes, lipid nanoparticles, polymeric micelles and mesoporous silica nanoparticles, together with their underlying mechanisms. The current review aims to provide a reliable basis and useful information for the development of new treatment strategies of multidrug resistance reversal using nanodrug delivery systems. IntroductionAt present, chemotherapy remains the optimal choice for cancer therapy, and tumor multidrug resistance (MDR) is a major factor that reduces the efficacy of chemotherapy (1). MDR is a phenotype that tumor cells acquire, which confers resistance to certain chemotherapy drugs, as well as concurrent cross-resistance to additional antitumor drugs that have different structures or mechanisms of action (2,3). The complexity of MDR has impeded the study of reversal agents (3-5). In recent years, the application of nanotechnology for drug carrier design has resulted in the development of novel nanoparticle drug delivery systems that aim to reverse MDR (6-8). Inorganic nanodrug delivery systems, lipid-based systems and polymer nanodrug delivery systems are the most common nanodrug delivery systems, which exhibit non-toxic, biocompatible and highly stable properties (8,9). The application of nanoparticle drug delivery systems is increasing due to their advantage of controlled and targeted drug release (9,10). Studies have demonstrated that entrapped small molecule drugs (10-200 nm in diameter) are more conducive to drug uptake and efflux; these nanodrug particles function via passive and active mechanisms, whereas in the systemic blood circulation they exhibit sustained release that subsequently enhances intracellular drug accumulation in tumor cells, yielding an improved effect (1,(11)(12)(13)(14). In the present review, the application of nanoparticle drug delivery systems in reversing the MDR of tumors is reviewed, which may provide an improved understanding of novel strategies for cancer therapy. Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer (Review)YINGHONG HUANG 1 , SUSAN P.C. COLE 2 , TIANGE CAI 3 , and YU CAI

show abstract

Section: Liposomesmentioning

confidence: 99%

Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Natural bioactive molecules have also been presumed to be safer than synthesized chemical compounds [2] . Many of these compounds have been identified as potential anticancer agents [3][4][5][6][7][8][9][10] . Physalis angulata L (Solanaceae) is a plant widely distributed throughout the tropical and subtropical regions of the world.…”

Section: Introductionmentioning

confidence: 99%

Physalin B not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in human colon cancer cells in vitro

Han

et al. 2015

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To investigate the effects of physalin B insolated from Physalis divericata on human colon cancer cells in vitro and its anticancer mechanisms. Methods: Human HCT116 colon cancer cell line was tested. Cell viability and apoptosis were detected, and relevant proteins were measured using Western blot analyses. Autophagosomes were observed in stable GFP-LC3 HCT116 cells. Localization of autophagosomes and lysosomes was evaluated in GFP-LC3/RFP-LAMP1-co-transfected cells. Microtubules and F-actin microfilaments were observed with confocal microscope. Mitochondrial ROS (mito-ROS) was detected with flow cytometry in the cells stained with MitoSox dye. Results: Physalin B inhibited the viability of HCT116 cells with an IC 50 value of 1.35 μmol/L. Treatment of the cells with physalin B (2.5-10 μmol/L) induced apoptosis and the cleavage of PARP and caspase-3. Meanwhile, physalin B treatment induced autophagosome formation, and accumulation of LC3-II and p62, but decreased Beclin 1 protein level. Marked changes of microtubules and F-actin microfilaments were observed in physalin B-treated cells, which led to the blockage of co-localization of autophagosomes and lysosomes. Physalin B treatment dose-dependently increased the phosphorylation of p38, ERK and JNK in the cells, whereas the p38 inhibitor SB202190, ERK inhibitor U0126 or JNK inhibitor SP600125 could partially reduce physalin B-induced PARP cleavage and p62 accumulation. Moreover, physalin B treatment dose-dependently increased mito-ROS production in the cells, whereas the ROS scavenger NAC could reverse physalin B-induced effects, including incomplete autophagic response, accumulation of ubiquitinated proteins, changes of microtubules and F-actin, activation of p38, ERK and JNK, as well as cell death and apoptosis. Conclusion: Physalin B induces mito-ROS, which not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in HCT116 cells in vitro.

show abstract

“…Liposomal anthracyclines proved to be effective and showed reduced cardiotoxicity when compared to free agents, either as a single agent or in combination with other drugs. 68,69 A meta-analysis study compared the safety and toxicity of liposomal Dox versus conventional anthracyclines. Both liposomal Dox and PEGylated liposomal Dox (PLD) showed favorable toxicity profiles, with better cardiac safety and less myelosuppression, alopecia, nausea, and vomiting compared with conventional anthracyclines, making them a favorable choice over conventional anthracyclines in elderly patients, patients with risk factors for cardiac disease, and patients with prior use of anthracyclines.…”

mentioning

confidence: 99%

Liposomes as nanomedical devices

Bozzuto¹,

Molinari²

2015

IJN

1,676

1,114

View full text Add to dashboard Cite

Since their discovery in the 1960s, liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for their biological and technological advantages, and are considered to be the most successful drug-carrier system known to date. Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be put on the market, or have already been approved for public use. In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, surface charge, and lipidic organization. Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ability to enter tissues, and final fate in vivo. Finally, we describe some strategies developed to overcome limitations of the “first-generation” liposomes, and liposome-based drugs on the market and in clinical trials.

show abstract

Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review

Cited by 137 publications

References 61 publications

Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer

Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer

Physalin B not only inhibits the ubiquitin-proteasome pathway but also induces incomplete autophagic response in human colon cancer cells in vitro

Liposomes as nanomedical devices

Contact Info

Product

Resources

About